286 related articles for article (PubMed ID: 21452327)
1. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
2. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
[TBL] [Abstract][Full Text] [Related]
3. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition.
Sekine H; Ruiz P; Gilkeson GS; Tomlinson S
Mol Immunol; 2011 Oct; 49(1-2):317-23. PubMed ID: 22000720
[TBL] [Abstract][Full Text] [Related]
4. Essential Roles for Mannose-Binding Lectin-Associated Serine Protease-1/3 in the Development of Lupus-Like Glomerulonephritis in MRL/
Machida T; Sakamoto N; Ishida Y; Takahashi M; Fujita T; Sekine H
Front Immunol; 2018; 9():1191. PubMed ID: 29892304
[TBL] [Abstract][Full Text] [Related]
5. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
6. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
Sekine H; Reilly CM; Molano ID; Garnier G; Circolo A; Ruiz P; Holers VM; Boackle SA; Gilkeson GS
J Immunol; 2001 May; 166(10):6444-51. PubMed ID: 11342671
[TBL] [Abstract][Full Text] [Related]
7. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.
Bao L; Haas M; Kraus DM; Hack BK; Rakstang JK; Holers VM; Quigg RJ
J Am Soc Nephrol; 2003 Mar; 14(3):670-9. PubMed ID: 12595503
[TBL] [Abstract][Full Text] [Related]
8. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
Huang Y; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2008 Dec; 181(11):8068-76. PubMed ID: 19017999
[TBL] [Abstract][Full Text] [Related]
9. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.
Kulik L; Laskowski J; Renner B; Woolaver R; Zhang L; Lyubchenko T; You Z; Thurman JM; Holers VM
J Immunol; 2019 Dec; 203(12):3136-3147. PubMed ID: 31732528
[TBL] [Abstract][Full Text] [Related]
11. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
Shi Y; Yao W; Sun L; Li G; Liu H; Ding P; Hu W; Xu H
BMC Nephrol; 2019 Nov; 20(1):424. PubMed ID: 31752725
[TBL] [Abstract][Full Text] [Related]
12. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice.
Chen K; Deng Y; Shang S; Tang L; Li Q; Bai X; Chen X
Biomed Pharmacother; 2022 Sep; 153():113433. PubMed ID: 36076550
[TBL] [Abstract][Full Text] [Related]
13. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
Rohrer B; Long Q; Coughlin B; Wilson RB; Huang Y; Qiao F; Tang PH; Kunchithapautham K; Gilkeson GS; Tomlinson S
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3056-64. PubMed ID: 19264882
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.
Ruseva MM; Peng T; Lasaro MA; Bouchard K; Liu-Chen S; Sun F; Yu ZX; Marozsan A; Wang Y; Pickering MC
J Am Soc Nephrol; 2016 Feb; 27(2):405-16. PubMed ID: 26047789
[TBL] [Abstract][Full Text] [Related]
15. Absence of functional alternative complement pathway alleviates lupus cerebritis.
Alexander JJ; Jacob A; Vezina P; Sekine H; Gilkeson GS; Quigg RJ
Eur J Immunol; 2007 Jun; 37(6):1691-701. PubMed ID: 17523212
[TBL] [Abstract][Full Text] [Related]
16. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease.
Lieberman LA; Mizui M; Nalbandian A; Bossé R; Crispín JC; Tsokos GC
Clin Immunol; 2015 Oct; 160(2):286-91. PubMed ID: 25988858
[TBL] [Abstract][Full Text] [Related]
17. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
[TBL] [Abstract][Full Text] [Related]
18. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Jiang C; Zhao ML; Scearce RM; Diaz M
Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
[TBL] [Abstract][Full Text] [Related]
19. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement.
Alawieh A; Elvington A; Zhu H; Yu J; Kindy MS; Atkinson C; Tomlinson S
J Neuroinflammation; 2015 Dec; 12():247. PubMed ID: 26714866
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis.
Sjöwall C; Olin AI; Skogh T; Wetterö J; Mörgelin M; Nived O; Sturfelt G; Bengtsson AA
Autoimmunity; 2013 May; 46(3):205-14. PubMed ID: 23331132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
